X-Chem and Orion Pharma Expand Collaboration to Accelerate Small Molecule Drug Discovery
• X-Chem and Orion Pharma have expanded their strategic collaboration from hit identification to candidate selection, leveraging DNA-encoded library technology and AI-driven approaches for multiple early-stage programs.
• The new Technology Access Agreement enables Orion to utilize X-Chem's integrated discovery capabilities, including DEL screening, AI-driven hit triage, and medicinal chemistry support to advance small molecule discovery.
• This partnership combines X-Chem's ArtemisAI platform with computational and medicinal chemistry expertise to help partners make informed decisions earlier in the discovery process, reducing risk and improving outcomes.
Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer
• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options.
• Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab.
• Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.
Advances in Metastatic Prostate Cancer: Novel Treatment Strategies Emerge
• The ARANOTE trial demonstrated that darolutamide plus ADT significantly improves radiographic progression-free survival in mHSPC patients.
• PEACE-3 trial results highlighted that combining radium-223 with enzalutamide significantly improved outcomes in mCRPC patients with bone metastases.
• SPLASH trial data suggests 177Lu-PNT2002 may offer a new radioligand therapy option for mCRPC patients who have progressed after an ARPI.
AI-Powered HASTEN Tool Accelerates Virtual Drug Screening 10-Fold
• Finnish researchers have developed an ML-powered tool called HASTEN that reduces virtual drug screening time from 6 months to under 10 days for 1.56 billion molecules.
• The system successfully identified 90% of top-scoring drug candidates when screening just 1% of the compound library against bacterial and viral targets.
• Orion Pharma and University of Eastern Finland researchers have made their datasets public to advance computational drug discovery research.
© Copyright 2025. All Rights Reserved by MedPath